Insiders bought alot of shares at prices greater than $6.41
Transaction Date Sorted in descending order. Name Position Type Shares Range Market
Value Total Holdings
03/07/2013 TERMEER, HENRI A. Director Buy 55,499 $6.73 373.7K 100,000
02/19/2013 YOUNG, ROBERT C. Director Buy 990 $6.60 6.5K 9,000
12/13/2012 KUCHERLAPATI, RAJU S. Director Buy 15,000 $6.65 - $6.75 99.7K 115,501
12/13/2012 YOUNG, ROBERT C. Director Buy 2,371 $6.78 - $6.78 16.1K 8,010
12/13/2012 TERMEER, HENRI A. Director Buy 5,200 $6.65 34.6K 44,501
12/13/2012 HA, NGOC TUAN Chief Executive Officer Buy 14,100 $6.85 96.6K 314,640
12/12/2012 TERMEER, HENRI A. Director Buy 39,301 $6.59 258.9K 39,301
12/12/2012 HA, NGOC TUAN Chief Executive Officer Buy 60,900 $6.61 402.3K 300,540
12/03/2012 YOUNG, ROBERT C. Director Buy 1,250 $6.41 8.0K 5,639
08/08/2012 YOUNG, ROBERT C. Director Buy 1,000 $8.63 8.6K 4,389
Which proves once again that both you and the noted insiders have very bad judgment. Here's a clue - this afternoon, the world could have bought much lower than you and the insiders. I know - this happens - but don't try to justify it - just accept it as a bad call.
I own shares for less than Henri Termeer....unbelievable....time will return rationality back to the market.
Henri Termeer has served as a member of our board of directors since June 2011. Mr. Termeer served as President and a member of the board of directors of Genzyme Corporation from 1983 until its acquisition by sanofi-aventis U.S., LLC in 2011, its Chief Executive Officer from 1985 to 2011 and the chairman of its board of directors from 1988 to 2011. He serves on the Council of Economic Advisors to Massachusetts Governor Deval Patrick and as co-chair of the Leadership Counsel of the Massachusetts Life Sciences Collaborative. Mr. Termeer is also chairman emeritus of the New England Healthcare Institute and a trustee for the Boston Museum of Science. Mr. Termeer serves on the board of directors of ABIOMED Inc., AVEO Pharmaceuticals, Inc., Massachusetts General Hospital, the Massachusetts Institute of Technology Corporation and Partners HealthCare, and, until December 31, 2011, served as chairman of the board of directors of the Federal Reserve Bank of Boston. Mr. Termeer also serves on the Board of Fellows of Harvard Medical School. He earned his M.B.A. from the Darden School at the University of Virginia. We believe Mr. Termeer is qualified to serve on our board of directors due to his senior executive experience in developing and managing Genzyme Corporation over the course of many years, his service on the boards of directors of Genzyme Corporation and other life sciences companies and his deep life sciences industry experience and knowledge.
I just added after seeing the Termeer purchase made not that long ago. I just have a small spec position for me. I think the votes should be for approval and the risk:reward, or upside to downside and valuation are compelling. If they do have to complete another trial, they will need to either sell, or rapidly cut costs, but they should be able to limit the downside if they take the right actions and Henri certainly has connections and credibility. All IMO, not advice and them market apparently disagrees so far.